NCT05585580View on ClinicalTrials.gov

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2026

Conditions
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Serplulimab

300mg d1 q3w

DRUG

Lenvatinib

8mg po qd

DRUG

Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome

135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w

Trial Locations (7)

250012

RECRUITING

Qilu hospital of Shandong univertisy, Jinan

RECRUITING

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan

RECRUITING

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan

264000

NOT_YET_RECRUITING

Yantai Yuhuangding Hospital, Yantai

266000

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

266011

RECRUITING

Qingdao Municipal Hospital（Group）, Qingdao

Unknown

NOT_YET_RECRUITING

Linyi Cancer Hospital, Linyi

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER